Minireview: New Molecular Mediators of Glucocorticoid Receptor Activity in Metabolic Tissues
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The glucocorticoid receptor (GR) was one of the first nuclear hormone receptors cloned and represents one of the most effective drug targets available today for the treatment of severe inflammation. The physiologic consequences of endogenous or exogenous glucocorticoid excess are well established and include hyperglycemia, insulin resistance, fatty liver, obesity, and muscle wasting. However, at the molecular and tissue-specific level, there are still many unknown protein mediators of glucocorticoid response and thus, much remains to be uncovered that will help determine whether activation of the GR can be tailored to improve therapeutic efficacy while minimizing unwanted side effects. This review summarizes recent discoveries of tissue-selective modulators of glucocorticoid signaling that are important in mediating the unwanted side effects of therapeutic glucocorticoid use, emphasizing the downstream molecular effects of GR activation in the liver, adipose tissue, muscle, and pancreas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799 · cited 1×
“Because AMP-activated kinase (AMPK) activates MAPK p38, this provides a mechanism by which the organism “senses” its low-energy status and turns off ATP-consuming metabolic programs including gluconeo-genesis (65).”
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102
Puigserver, P., & Spiegelman, B. M. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0012 · Cited by 2,076
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“), glucocorticoid receptor interacting protein 1, p160 transcriptional cofactor steroid receptor coactivator 1 (SRC-1), and the acetyltransferase p300/cAMP response element binding protein (CREB)-binding protein (CBP) are also involved in Pepck transactivation (20, 53–56).”
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487 · cited 1×
“, CREB, and FOXO1) (58, 59).”
Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors
Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232 · cited 2×
“In a second example, Holland et al (79) showed that Dex treatment increases ceramide synthesis and accumulation in the liver by inducing the expression of ceramide synthetic genes including serine palmitoyltransferase, the rate-limiting enzyme in ceramide synthesis.”
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 1×
“Inhi-1002 bition of HDAC6 activity results in hyperacetylation of Hsp90 and impaired chaperone-dependent activation of GR (74, 75).”
Chromatin accessibility pre-determines glucocorticoid receptor binding patterns
John, S., Sabo, P. J., Thurman, R. E., Sung, M.-H., Biddie, S. C., Johnson, T. A., Hager, G. L., & Stamatoyannopoulos, J. A. (2011) · Nature Genetics · doi:10.1038/ng.759 · Cited by 954 · cited 4×
“Moreover, comparing different GBSs to the DNase accessibility of those same sites demonstrated that approximately half of the GBS motifs had an absolute requirement for accessible chromatin in A549 lung carcinoma cells (34, 42).”
InfluentialTRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver
Du, K., Herzig, S., Kulkarni, R. N., & Montminy, M. (2003) · Science · doi:10.1126/science.1079817 · Cited by 842 · cited 2×
“Du et al (78) found that TRB3 functions as a negative modulator of insulin signaling where it binds directly to AKT, preventing its phosphorylation and activation in diabetic db/db mouse livers, in turn promoting hyperglycemia and glucose intolerance (78).”
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
RIZZA, R. A., MANDARINO, L. J., & GERICH, J. E. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-1-131 · Cited by 696
The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683 · cited 2×
“MuRF1 has been shown to physically interact with the myosin heavy chain of skeletal muscle to target it for degradation, and the loss of myosin heavy chain in response to GCs is attenuated in Murf1-/- mice (106).”
DNA binding site sequence directs glucocorticoid receptor structure and activity
Meijsing, S. H., Pufall, M. A., So, A. Y., Bates, D. L., Chen, L., & Yamamoto, K. R. (2009) · Science · doi:10.1126/science.1164265 · Cited by 673 · cited 1×
“…that tissue, cell, and gene-specific effects of GR activation are orchestrated by many factors including the tissue-specific presence of coregulatory proteins, different GR isoforms, the phosphorylation status of GR, and the sequence of the GR-binding site and flanking DNA on target genes (32, 33).”
Wang, X., Hu, Z., Hu, J., Du, J., & Mitch, W. E. (2006) · Endocrinology · doi:10.1210/en.2006-0251 · Cited by 600
Reddy, T. E., Pauli, F., Sprouse, R. O., Neff, N. F., Newberry, K. M., Garabedian, M. J., & Myers, R. M. (2009) · Genome Research · doi:10.1101/gr.097022.109 · Cited by 543
Glucocorticoids, metabolism and metabolic diseases
Vegiopoulos, A., & Herzig, S. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.015 · Cited by 535
Transcription Factor AP1 Potentiates Chromatin Accessibility and Glucocorticoid Receptor Binding
Biddie, S. C., John, S., Sabo, P. J., Thurman, R. E., Johnson, T. A., Schiltz, R. L., Miranda, T. B., Sung, M.-H., Trump, S., Lightman, S. L., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.016 · Cited by 503
Lambillotte, C., Gilon, P., & Henquin, J. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119175 · Cited by 419 · cited 1×
“In contrast to the above experiments in which GCs were administered subchronically in vivo, mechanistic studies performed in tissue culture using isolated islets and insulin-producing cells show that GC treatment inhibits insulin secretion and increases (cid:2) -cell apoptosis (11, 137, 138).”
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419 · cited 2×
“…novo gluconeogenesis (liver) while also increasing protein catabolism (muscle) and lipolysis (adipose) to provide substrates for glucose production by the liver. of signal transduction through interactions involving cytosolic GR or specific membrane-bound receptor as reviewed by Stahn et al (38).”
Prevalence of oral glucocorticoid usage in the United States: a general population perspective
Overman, R. A., Yeh, J., & Deal, C. L. (2013) · Arthritis Care & Research · doi:10.1002/acr.21796 · Cited by 405 · cited 1×
“It is estimated that 1.2% of the US population is currently being treated with a prescription GC drug (21).”
InfluentialOakley, R. H., & Cidlowski, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.179325 · Cited by 373 · cited 1×
“…deleterious side effects in humans and rodents including dysregulation of glucose and fat metabolism, hepatosteatosis, insulin resistance, diabetes, osteoporosis, muscle wasting, growth retardation, infertility, cognitive dysfunction, glaucoma, cataracts, and topical skin thinning (1, 3, 5, 22–26).”
Vandevyver, S., Dejager, L., Tuckermann, J., & Libert, C. (2013) · Endocrinology · doi:10.1210/en.2012-2045 · Cited by 296 · cited 1×
“This dogma has recently been questioned (28) because dimerization and transactivation of GR are both unequivocally important for its antiinflammatory function (29, 30).”
High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278 · cited 1×
“Abdominal obesity is strongly associated with insulin resistance, cardiovascular disease, and hypertension and thus is a significant contributor to morbidity and mortality (93–95).”
Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects
Kassel, O., & Herrlich, P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.003 · Cited by 277
Uhlenhaut, N. H., Barish, G. D., Yu, R. T., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hübner, N., & Evans, R. M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.013 · Cited by 265 · cited 3×
“In the nucleus, it activates or represses transcription of distinct sets of genes either by directly binding to specific DNA sequences (glucocorticoid response elements[GREs])orthroughdirectpro-tein-protein interactions with other transcription factors and/or coregula-tors (Figure 2A) (30, 36, 37).”
Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids
Baehr, L. M., Furlow, J. D., & Bodine, S. C. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.212845 · Cited by 234 · cited 1×
“Using Dex to induce muscle atrophy, Baehr et al (109) found that Murf1-/- mice exhibited muscle sparing compared with Wt mice; however, this was not observed in Mafbx-/- mice, indicating that MuRF1 and MAFbx are differentially sensitive to various atrophy models (109).”
Grøntved, L., John, S., Baek, S., Liu, Y., Buckley, J. R., Vinson, C., Aguilera, G., & Hager, G. L. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.106 · Cited by 229 · cited 1×
“ChIP-seq studies performed in mouse liver found that genes activated and repressed by GR are actively remodeled upon GC treatment (ie, have altered DNase hyper-sensitivity sites [43]).”
Adipogenic and lipolytic effects of chronic glucocorticoid exposure
Campbell, J. E., Peckett, A. J., D'souza, A. M., Hawke, T. J., & Riddell, M. C. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00045.2010 · Cited by 228 · cited 2×
“Campbell et al (99) found that treatment of rats with corticosterone for 10 days also increased visceral adiposity due to increased preadipocyte differentiation as opposed to adipocyte hypertrophy.”
Stimulation of Lipolysis in Humans by Physiological Hypercortisolemia
Divertie, G. D., Jensen, M. D., & Miles, J. M. (1991) · Diabetes · doi:10.2337/diab.40.10.1228 · Cited by 201
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Koliwad, S. K., Kuo, T., Shipp, L. E., Gray, N. E., Backhed, F., So, A. Y.-L., Farese, R. V., & Wang, J.-C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025452 · Cited by 164
Reddy, T. E., Gertz, J., Crawford, G. E., Garabedian, M. J., & Myers, R. M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00062-12 · Cited by 149 · cited 1×
“Moreover, comparing different GBSs to the DNase accessibility of those same sites demonstrated that approximately half of the GBS motifs had an absolute requirement for accessible chromatin in A549 lung carcinoma cells (34, 42).”
Insulin action and signalling in fat and muscle from dexamethasone-treated rats
Burén, J., Lai, Y. C., Lundgren, M., Eriksson, J. W., & Jensen, J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.02.034 · Cited by 125 · cited 1×
“However, following GC treatment, glycogen synthase kinase 3 phosphorylation is decreased, which activates it, leading to repression of glycogen synthase (123).”
Metabolic Adaptations to Dexamethasone‐Induced Insulin Resistance in Healthy Volunteers
Nicod, N., Giusti, V., Besse, C., & Tappy, L. (2003) · Obesity Research · doi:10.1038/oby.2003.90 · Cited by 125
Gray, N. E., Lam, L. N., Yang, K., Zhou, A. Y., Koliwad, S., & Wang, J.-C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294124 · Cited by 116 · cited 3×
“Subsequent studies by Gray et al (101) showed that 24 hours of fasting induced Angptl4 expression in the liver and WAT in a GR-dependent manner (the effect was attenuated by RU-486 treatment).”
InfluentialCardiovascular risk in Cushing’s syndrome
Arnaldi, G., Mancini, T., Polenta, B., & Boscaro, M. (2004) · Pituitary · doi:10.1007/s11102-005-1172-7 · Cited by 103
Rafacho, A., Marroquí, L., Taboga, S. R., Abrantes, J. L. F., Silveira, L. R., Boschero, A. C., Carneiro, E. M., Bosqueiro, J. R., Nadal, A., & Quesada, I. (2010) · Endocrinology · doi:10.1210/en.2009-0704 · Cited by 80 · cited 1×
“In contrast, a recent study in rat islets isolated from Dex-treated animals demonstrated that more docked secretory granules are present in the (cid:2) -cells, resulting in enhanced insulin secretion in response to glucose (134).”
HES1 is a master regulator of glucocorticoid receptor-dependent gene expression
Revollo, J. R., Oakley, R. H., Lu, N. Z., Kadmiel, M., Gandhavadi, M., & Cidlowski, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004389 · Cited by 50 · cited 1×
“A recent study using Dex-treated Hes1 liver-specific knockout mice found that Hes1 plays a more global role as a master repressor that must first be down-regulated for GR to have its effects on carbohydrate metabolism (89).”
Effect of hypercorticism on regulation of skeletal muscle glycogen metabolism by insulin
Coderre, L., Srivastava, A. K., & Chiasson, J. L. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.262.4.e427 · Cited by 17 · cited 1×
“Moreover, glycogen synthase activity is decreased following GC treatment (5, 121, 122).”
Cited by
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Glucocorticoid receptor control of transcription: precision and plasticity via allostery
Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.152 · Cited by 533
Kraemer, W. J., Ratamess, N. A., Hymer, W. C., Nindl, B. C., & Fragala, M. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00033 · Cited by 300
Glucocorticoid therapy and ocular hypertension
Dibas, A., & Yorio, T. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.018 · Cited by 75
Glucocorticoids have opposing effects on liver fibrosis in hepatic stellate and immune cells
Kim, K. H., Lee, J. M., Zhou, Y., Harpavat, S., & Moore, D. D. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1029 · Cited by 41
Metadata
- Authors
- Patel, R., Williams-Dautovich, J., & Cummins, C. L.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-07-01
- Volume
- 28
- Issue
- 7
- Pages
- 999-1011
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2165175562
- Cited by
- 108
- References
- 43
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.